Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations.
Deschamps R, Papeix C, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deiva K, Durand Dubief F, Laplaud DA, Maillart E, Michel L, Pique J, Ruet A, Thouvenot E, Zéphir H, Marignier R, Audoin B.
Deschamps R, et al.
Rev Neurol (Paris). 2024 Oct;180(8):711-714. doi: 10.1016/j.neurol.2024.06.003. Epub 2024 Jul 4.
Rev Neurol (Paris). 2024.
PMID: 38969609
No abstract available.